Box News

No — suramin alone would not cure eczema or psoriasis; key elements are missing.

Even ignoring toxicity, suramin only blocks some inflammatory signalling (mainly ATP-driven pathways). Eczema and psoriasis are complex diseases involving skin barrier defects, genetic factors, dysregulated adaptive immunity (T cells, cytokines like IL-17/IL-23 or IL-4/IL-13), microbiome interactions, and long-term immune memory. Suramin does not correct the skin barrier, does not selectively reset pathogenic immune circuits, and does not provide durable, localized control. At best it could temporarily dampen inflammation, not cure the disease.

Eczema and Psoriasis as Multilevel Diseases: Implications for Therapeutic Strategy

Even if you ignore the toxicity question, suramin by itself is unlikely to cure eczema or psoriasis because those diseases are complex, multi-layered problems — not just single overactive inflammatory pathways that one drug can switch off. At a basic level, both conditions arise from a combination of tissue-level changes, long-lived adaptive immune programs, and environmental or microbial influences. A single, broad inhibitor like suramin can blunt some inflammatory signals, but it does not correct the structural, cellular and immune memory problems that sustain these disorders.

Take eczema (atopic dermatitis) as an example. A central feature is a defective skin barrier: the outermost cells and lipids that normally keep moisture in and allergens and microbes out are impaired. That barrier defect allows irritants and microbes to enter, which repeatedly trigger immune responses and scratching that further damage the skin. The dominant immune signature in eczema is driven by adaptive immune cells — particularly Th2-type T cells that make cytokines such as IL-4 and IL-13 — and by long-lived populations of skin-resident memory T cells that reawaken on exposure to triggers. Effective long-term control therefore requires repairing the barrier (emollients, lipid replacement), reducing specific adaptive immune drivers, and controlling itch and microbial colonization. Suramin’s main actions — blocking extracellular-nucleotide signalling and some growth-factor pathways — may reduce short-term innate inflammation, but they do not restore barrier function, selectively reprogram pathogenic T cells, or remove the resident immune memory that causes relapses.

Psoriasis illustrates the same limitation from a different angle. Psoriasis is driven by a well-defined adaptive immune circuit centred on the IL-23 → IL-17 axis, which stimulates keratinocytes to proliferate and form thick, scaly plaques. Genetic predisposition, keratinocyte-intrinsic changes, and a reinforcing loop between immune cells and skin cells create a self-sustaining disease state. Therapies that have been most successful at producing long-term clearance target specific cytokines in this loop (for example IL-17 or IL-23 inhibitors) or modulate T-cell activity. Suramin’s broad blockade of purinergic and growth-factor signalling can lower some inflammatory mediators, but it does not selectively interrupt the IL-23/IL-17 circuit, nor does it normalize the altered keratinocyte behaviour that produces the plaque. Consequently, any benefit would likely be partial and transient.

There are also important spatial and temporal considerations. Eczema and psoriasis are primarily localized skin diseases that often benefit from topical or tissue-directed treatments that limit systemic exposure and focus therapy where it is needed. Suramin is not formulated as a safe, effective topical modulator of the precise receptors that matter in the skin, and its non-selective systemic action would not provide the targeted, sustained modulation of pathogenic immune pathways required for durable remission. Moreover, many aspects of disease progression — microbial dysbiosis, barrier lipid composition, neurosensory itch circuits and tissue-resident immune memory — are not addressed by blocking extracellular ATP signalling alone.

Finally, “cure” implies resetting the system so it no longer returns to disease. That usually requires durable changes: repair of the physical barrier, elimination or durable suppression of pathogenic adaptive immune clones, and correction of host–microbe interactions. Suramin may transiently reduce inflammatory signals and could be useful experimentally to show that nucleotide signalling contributes to a flare, but it lacks the specificity and the set of actions needed to produce a lasting cure.

In short, suramin might dampen certain inflammatory processes that contribute to eczema or psoriasis, but it does not correct barrier defects, does not selectively rewire the adaptive immune circuits that drive chronic disease, and does not address the microbiome or tissue-resident immune memory. For those reasons, even leaving safety aside, suramin alone is not a realistic path to cure; successful long-term control or remission requires a combination of targeted immune modulation, barrier repair, and management of environmental and microbial triggers.

(Source : ChatGPT)

Suramin can alter immune regulation because it interferes with several of the molecular “switches” immune cells use to decide whether to turn inflammation up or down. Saying this another way: suramin doesn’t act like a single, targeted immune drug; it bluntly interrupts multiple communication channels between cells. That blunt interruption can reduce harmful inflammatory signals in the short term, which is why researchers have studied the drug as an experimental immune modulator — but the same broad action is also the reason it is unsafe for routine therapy.

At a molecular level the most important effect is on purinergic signalling. Cells under stress or damage release ATP into the space outside themselves, and that extracellular ATP is read by purinergic receptors on immune and tissue cells. One of those receptors, P2X7, is a powerful trigger of inflammation: when ATP opens P2X7 it allows calcium and other ions into the cell, this promotes assembly of the NLRP3 inflammasome, and that pathway converts inactive cytokine precursors into active inflammatory cytokines such as interleukin-1β. Suramin binds to and blocks many P2 (P2X and P2Y) receptor subtypes, so it prevents ATP from activating these receptors. The immediate consequence is less ion flux, reduced inflammasome assembly, and therefore lower release of key inflammatory cytokines. In models where excessive ATP-driven signalling sustains tissue inflammation, this mechanism explains the anti-inflammatory effect of suramin.

Suramin’s actions are not limited to purinergic receptors. The molecule also interferes with several growth-factor and extracellular signalling proteins. In immune terms, this can reduce the stimulatory signals that dendritic cells use to mature and present antigen, and it can blunt growth-factor–driven survival signals that support expansion of pro-inflammatory cell populations. Put together, these effects reduce antigen presentation, lower T-cell activation and proliferation in some contexts, and can shift cytokine balances away from strongly pro-inflammatory patterns (for example reducing IL-1β, IL-6 and downstream Th17-type responses that drive many autoimmune and inflammatory diseases).

At the cellular and tissue level these molecular changes translate into measurable shifts in immune behaviour. Macrophages exposed to suramin tend to produce fewer inflammasome-dependent cytokines and adopt less aggressively inflammatory phenotypes in laboratory studies. Dendritic cells are less effective at activating naïve T cells when purinergic signals are blocked. In certain animal models of sterile inflammation or organ injury, suramin treatment reduces immune cell recruitment, lowers tissue cytokine levels and improves short-term histological outcomes. These observations support the idea that suramin can act as an immune dampener when pathology is driven by extracellular nucleotide signalling or by overactive growth-factor–dependent immune stimulation.

However, there are important caveats that matter for any practical use. Because suramin is non-selective it also blocks purinergic and growth-factor signals that are essential for host defence, wound healing and normal tissue maintenance. Blocking P2 receptors can impair immune responses needed to clear infections; inhibiting growth-factor signalling can harm neurons, renal tubular cells and bone-marrow progenitors. Suramin’s long tissue half-life means that any beneficial immune dampening may be accompanied by prolonged undesirable suppression or organ toxicity. In short, while suramin can reduce pathological inflammatory signalling by interrupting ATP-driven and growth-factor pathways, those same mechanisms underlie many of its serious side effects.

To summarize: suramin can help regulate the immune system by blocking extracellular-nucleotide receptors (reducing inflammasome activation and pro-inflammatory cytokine release) and by dampening growth-factor–mediated immune stimulation. These actions produce clear anti-inflammatory effects in experimental settings, but the drug’s broad, non-selective blockade and long persistence in tissues make it unsuitable as a safe immune-regulating medication in routine clinical practice. Researchers therefore view suramin more as a proof-of-concept or research tool and seek to reproduce its benefits with much more selective and safer approaches.

(Source : ChatGPT)

Short introduction

Inflammation in the body is tightly controlled by extracellular signalling systems that can either amplify immune responses or help bring them back under control once a threat has passed. One of the most important of these systems is purinergic signalling, which uses ATP and its breakdown product adenosine to communicate danger, stress, and resolution between cells. While ATP-driven signalling is often associated with inflammation, the same network also contains specific receptors and enzymes that actively reduce harmful immune activation and promote tissue protection. Understanding which purinergic receptors have anti-inflammatory roles, how they are activated, and how they function at the cellular level is essential for interpreting immune regulation in diseases such as autoimmunity, chronic inflammation, and tissue injury.

The purinergic system that dials inflammation up or down includes two broad classes of targets: the adenosine (P1) receptors, which most reliably reduce harmful inflammation, and a smaller set of P2 (ATP/ADP) receptors that in some cells promote homeostasis rather than inflammation. The key receptors you should know by name are the adenosine A₂A receptor (gene ADORA2A), the adenosine A₂B receptor (ADORA2B), and the adenosine A₃ receptor (ADORA3). These P1 receptors are activated by extracellular adenosine, the breakdown product of ATP, and when engaged they trigger intracellular signalling (most often raising cyclic AMP) that suppresses inflammatory pathways, reduces production of pro-inflammatory cytokines (for example IL-1β, TNF and IL-6), and promotes tissue-protective processes such as epithelial repair and regulatory T-cell activity. The anti-inflammatory role of A₂A is especially well documented across immune cell types, while A₂B and A₃ also contribute to tissue protection and immune regulation in many experimental and clinical settings. (PMC)

Those adenosine receptors do not work alone: two cell-surface enzymes, CD39 and CD73, are central to creating the anti-inflammatory signal because they convert extracellular ATP (a “danger” molecule) stepwise into adenosine. By increasing local adenosine, CD39/CD73 indirectly activate the A₂ and A₃ receptors and so shift the local immune environment toward resolution and suppression of excessive inflammation. This CD39–CD73 → adenosine → A₂A/A₂B/A₃ axis is widely regarded as a master regulator of immunosuppression in tissues. (jitc.bmj.com)

Among P2 (ATP/ADP) receptors, the picture is more mixed: some P2X family members (for example P2X7) are pro-inflammatory, but certain P2Y receptors can play anti-inflammatory or homeostatic roles in specific cell types. Notably, P2Y11 in human macrophages has been shown to cooperate with other receptors to restrain inflammatory responses and promote resolution programs, in part by engaging cAMP-linked signalling. In the brain, P2Y12 on microglia supports surveillance and homeostatic behaviour; loss or overactivation of P2Y12 is linked to maladaptive microglial responses, so P2Y12 is often described as a “safeguarding” receptor that helps prevent excessive neuroinflammation. These P2Y receptors therefore can indirectly reduce harmful inflammation by steering immune cells toward repair and away from destructive activation — but their effects are highly cell- and context-dependent. (PMC)

At the mechanistic level, activation of the adenosine receptors (A₂A/A₂B/A₃) typically increases intracellular cyclic AMP and activates downstream kinases that inhibit NF-κB and other pro-inflammatory transcription factors, lower reactive oxygen species and inflammasome activation, and promote anti-inflammatory mediators and regulatory cell types. In contrast, P2Y-type anti-inflammatory signalling (for example P2Y11) may use a mix of G-protein signals to both raise cAMP and cross-talk with cytokine receptors (such as the IL-1 receptor) to blunt inflammatory outputs. Because these pathways converge on shared molecular switches (cAMP, NF-κB, inflammasomes), they can effectively tone down inflammation when adenosine levels are high or when particular P2Y receptors are engaged. (PMC)

In plain terms: if you want the names to look for in the literature or to appear in a figure, focus on ADORA2A (A₂A), ADORA2B (A₂B) and ADORA3 (A₃) as the principal anti-inflammatory purinergic receptors, with CD39/CD73 as the enzymes that make adenosine. For context-dependent, homeostatic P2 receptors that can also limit harmful inflammation in certain cells, the most relevant names are P2Y11 and P2Y12. Each of these receptors works by changing intracellular signalling (often via cAMP) to reduce cytokine release, suppress inflammasome activity, and encourage repair rather than destructive inflammation. (PMC)

(Source : ChatGPT)

Suramin can produce real and sometimes serious harm, and understanding the likely side effects together with the biological reasons they happen helps explain why the drug is used only in tightly controlled settings. Below I explain the main dangers, what people actually experience, and the mechanisms scientists think are responsible — in plain language.

The single most important clinical danger is nerve injury: suramin commonly causes a dose-related peripheral neuropathy. Patients treated with suramin in cancer and other trials have developed numbness, tingling, weakness in the hands and feet and, in some cases, a more severe demyelinating syndrome resembling Guillain–Barré. This is not a subtle lab finding — neuropathy was frequently dose-limiting in older clinical studies and appears in many modern safety reviews. The neuropathy is thought to arise because suramin is a charged molecule that distributes to peripheral nerves and interferes with normal neuronal signalling and axonal function; because it does not readily cross the blood–brain barrier, the problem predominantly affects the peripheral nervous system. (PMC)

Kidney damage is another major and well-documented risk. Clinical records and trial summaries report rises in serum creatinine, proteinuria and clinically significant renal impairment in a substantial minority of patients, and preclinical studies show that suramin accumulates in kidney tissue. The likely mechanisms are multifactorial: direct toxic effects on renal tubular cells (partly from local drug accumulation), interference with growth-factor signalling that helps maintain renal architecture, and indirect effects from systemic changes such as altered coagulation or inflammatory responses. Because the kidneys concentrate and retain suramin, renal toxicity is both common and important to monitor. (ScienceDirect)

Suramin has a very long plasma half-life and sticks to proteins and tissues, which makes side effects persistent. Pharmacokinetic studies show elimination half-lives measured in weeks (commonly reported in the range of ~30–60 days), and suramin can be detected in urine or plasma for many weeks to months after a dose. The consequence is that adverse effects may appear late, worsen with repeated dosing, and take a long time to resolve after stopping the drug — so even a small overdose or an otherwise modest toxic effect can become prolonged. This very slow clearance narrows the gap between an effective dose and a harmful one. (PubMed)

Beyond nerves and kidneys, suramin causes a range of systemic toxicities. Infusion or hypersensitivity reactions, skin rashes and severe dermatologic events (including rare reports of toxic epidermal necrolysis), bone-marrow suppression (leading to anemia, neutropenia or thrombocytopenia), elevated liver enzymes, and general constitutional symptoms (fatigue, nausea) have all been reported. Suramin has also been associated with coagulopathy and, in older reports, with adrenal insufficiency and multiorgan problems when toxicity is severe. These effects reflect both immune/hypersensitivity phenomena and the drug’s broad interference with multiple cellular pathways. (Mayo Clinic)

Mechanistically, suramin’s harms flow logically from what the molecule does at the molecular level. Suramin is a large, highly negatively charged (polyanionic) compound that binds to many proteins on cell surfaces and in extracellular fluid. It blocks multiple purinergic receptors (P2X and P2Y families) and also interferes with growth-factor receptors and other signalling proteins. Blocking purinergic receptors can reduce harmful inflammation in some situations, but those same receptors are also needed for normal nerve signalling, renal tubular transport, immune surveillance and wound repair. Similarly, inhibiting growth-factor pathways can slow tumour growth in some models but also impair the survival and maintenance of normal cells (including neurons, kidney cells, and bone marrow progenitors). The combination of broad receptor blockade plus tissue accumulation explains why suramin’s side effects are both varied and sometimes severe. (PMC)

There are also specific molecular processes implicated in particular toxicities. For example, blocking P2X7 and related purinergic signalling can alter calcium fluxes and inflammasome activation in immune cells — effects that can be anti-inflammatory in one context but disruptive in another. Neuronal dysfunction may result from disturbed ion channel activity and impaired neurotrophic (growth-factor) signalling. Renal injury likely reflects direct tubular cell exposure and disrupted local signalling needed for normal filtration and reabsorption. Bone-marrow effects probably reflect interference with cytokine/growth-factor pathways that control blood cell production. Because suramin hits many of these systems at once, multiple organ systems can be affected simultaneously. (Frontiers)

Clinically, those facts translate into clear cautions. Suramin is given intravenously and requires careful dose selection, baseline assessment of kidney function and blood counts, and close monitoring during and for many weeks after treatment. Repeated dosing risks accumulation and delayed toxicity; symptoms such as new numbness, weakness, changes in urine output, unexpected bleeding or signs of infection should prompt immediate medical review. Because of the toxicity profile and the availability of safer, more selective drugs for most conditions, suramin today is reserved for a very small set of indications or tightly controlled experimental protocols. (Dove Medical Press)

In short, suramin’s dangers are not random — they stem from the drug’s non-selective blockade of multiple cell-surface receptors and growth signals combined with very slow elimination and tissue accumulation. That biological picture explains why the observed side effects cluster in the nervous system, the kidneys, the blood and the skin, and why those effects can be prolonged and clinically serious. For these reasons, any use of suramin must be medically supervised, limited to appropriate indications or clinical trials, and accompanied by careful monitoring. (PMC)

(Source : ChatGPT)

Could Suramin Treat Eczema? Yes — in theory it could help, but in practice it is not a safe or established treatment, and the reasons matter.

Eczema (atopic dermatitis) and psoriasis are inflammatory skin diseases in which purinergic signalling plays a meaningful role. In inflamed skin, damaged keratinocytes and immune cells release extracellular ATP. That ATP activates purinergic receptors—especially P2X7 and certain P2Y receptors—on keratinocytes, dendritic cells, macrophages and T cells. Activation of these receptors promotes release of pro-inflammatory cytokines (such as IL-1β, IL-6, IL-17 and TNF-α), enhances inflammasome activity, and sustains immune cell recruitment into the skin. This ATP-driven signalling contributes to chronic inflammation, epidermal hyperproliferation (particularly in psoriasis), itching, and barrier dysfunction.

Because suramin broadly blocks P2X and P2Y receptors, it can suppress ATP-mediated inflammatory signalling. In experimental systems, blocking purinergic receptors reduces inflammasome activation, cytokine release, immune cell activation and keratinocyte overstimulation—all processes involved in eczema and psoriasis. For this reason, anti-purinergic strategies are being actively explored in dermatology research, and selective P2X7 antagonists have shown anti-inflammatory effects in animal models of skin disease.

However, suramin itself is not a practical or safe option for these conditions. Its effects are non-selective and systemic, it must be given intravenously, and it carries substantial risks including nerve toxicity, kidney damage, and long-lasting accumulation in tissues. Skin diseases like eczema and psoriasis require long-term management, whereas suramin is unsuitable for chronic use and cannot be localized to the skin in a controlled way. In addition, purinergic signalling also contributes to normal skin repair, antimicrobial defense, and wound healing, so broad blockade risks impairing essential skin functions.

In summary: the mechanism suramin acts on is relevant to eczema and psoriasis, and its anti-purinergic action explains why similar pathways are considered therapeutic targets. But suramin itself is not an appropriate or approved treatment. Current and future therapies aim to mimic its beneficial anti-purinergic effects using much more selective, safer, and often topical agents, rather than a broad, high-toxicity drug like suramin.

The Risks of Non-Selective Pharmacological Action: Lessons from Suramin

Non-selective means a drug affects many different targets in the body instead of one specific protein or pathway. For a compound like suramin, that broad activity is a double-edged sword: it makes the drug useful in experiments because it can blunt a whole class of signals at once, but it also makes the effects messy, unpredictable, and often harmful when you try to use the drug in people.

When a medicine hits many receptors and pathways, some of those pathways are ones you want to block and others are ones the body needs for normal health. Purinergic receptors, growth-factor receptors and related signalling proteins that suramin interferes with are involved not only in pathological inflammation but also in essential processes such as nerve signalling, kidney filtration, wound healing, and defence against infections. Blocking them all at once can therefore reduce harmful inflammation but at the same time impair tissue repair, weaken immune responses to microbes, or damage sensitive organs. That explains why patients given broadly acting drugs sometimes develop nerve symptoms, kidney problems, or other unexpected toxicities: the drug has shut down helpful biology along with the harmful biology.

Non-selectivity also makes dosing and timing much harder. With a selective drug you can aim the dose to affect the target that causes disease while leaving other systems relatively intact; with a non-selective drug the margin between an effective dose and a harmful dose is often much smaller. Suramin is long-lasting and accumulates in tissues, so any unwanted effects may persist long after dosing stops, and it is difficult to reverse them quickly. This creates what clinicians call a narrow therapeutic index — small increases in dose can change a helpful effect into a dangerous one — which is especially problematic for conditions that require long-term treatment, such as chronic skin diseases.

Another problem is variability between patients. People differ in which receptors are most active, in how their organs clear drugs, and in how sensitive their tissues are to signalling changes. A non-selective drug that is tolerable in one person may cause severe problems in another, so safety becomes unpredictable and clinical trials and regulatory approval are much more difficult. Non-selective drugs are also more likely to interact with other medications because they perturb multiple pathways that drugs commonly target.

Finally, non-selectivity obscures understanding of mechanism. If a patient improves after receiving a broad-acting drug, it can be hard to tell which blocked pathway produced the benefit. That makes it harder to design safer, more targeted therapies that reproduce the benefit without the harm. For these reasons drug development generally favors agents that are selective for the disease-relevant receptor subtype, that can be delivered locally (for example topically to skin), or that modulate signalling only in specific cells or disease stages. Such approaches aim to preserve the helpful roles of the targeted pathways — wound repair, host defence, normal metabolism — while reducing the pathological signalling that drives disease.

In short, suramin’s non-selective action explains both its experimental usefulness and its unsuitability as a safe, long-term therapeutic: by hitting too many targets at once it increases the risk of damaging normal physiology, creates dosing and monitoring challenges, and makes adverse effects harder to predict and manage.

(Source : ChatGPT)

Here’s a plain-language, didactical explanation of what suramin does to purinergic (ATP/adenosine) signalling and why those effects matter.

Suramin is a large, negatively charged drug that, among many other actions, binds to and blocks purinergic receptors — the proteins on cell surfaces that detect extracellular ATP and related nucleotides. Because extracellular ATP is a widely used “danger” signal in tissues, blocking those receptors reduces the ability of cells to sense ATP and therefore blunts many downstream responses that would normally follow tissue stress or immune activation. In practical terms, suramin behaves like a broad-spectrum P2 receptor antagonist: it interferes with both ion-channel type P2X receptors and G-protein coupled P2Y receptors so that ATP (and some other nucleotides) cannot trigger their usual cellular effects. (PMC)

At the level of single cells this receptor blockade has several predictable consequences. For ion-channel P2X receptors (for example P2X7), ATP normally opens a channel that allows calcium and other ions to flow into the cell; this ion flux is a key step for assembling the NLRP3 inflammasome and releasing inflammatory cytokines such as interleukin-1β. By preventing ATP from activating those channels, suramin reduces calcium influx, inhibits inflammasome assembly in many experimental systems, and thereby lowers ATP-driven IL-1β release and related inflammatory signalling. For metabotropic P2Y receptors, suramin’s blockade prevents G-protein signalling cascades that would otherwise change cell migration, cytokine production, or gene expression. Those combined effects explain why suramin can potently damp down nucleotide-driven inflammation in laboratory and animal studies. (PMC)

Because suramin is non-selective (it binds many P2 subtypes with only modest preference) its effects are broad rather than narrowly targeted. That breadth can be useful experimentally — suramin is commonly used as a research tool to show that a response is purinergic — but it also means the drug affects many cell types and signalling pathways at once. In tissues this translates to multi-level modulation: innate immune cells (macrophages, dendritic cells, neutrophils) show less ATP-driven activation; some lymphocyte functions that depend on nucleotide signals are altered; and non-immune cells such as endothelial or epithelial cells change their responses to injury. The non-selective character of suramin therefore produces both anti-inflammatory benefits in models and a risk of unintended disruption of normal purinergic functions. (PMC)

The net physiological consequences depend strongly on context. In disease models where excessive extracellular ATP drives pathology — for example in some forms of sterile inflammation, models of kidney injury, or certain neuroinflammatory settings — suramin’s blockade of P2 receptors reduces tissue inflammation and damage. Multiple preclinical studies report less inflammasome activation, lower cytokine release, and improved outcomes after suramin treatment in such settings. However, because ATP-dependent purinergic signalling is also important for host defence, tissue repair, and normal cell communication, chronic or systemic blockade can impair beneficial responses (for instance responses to infection or normal wound healing) and contributes to the drug’s toxicity profile in humans and animals. (Wiley Online Library)

Mechanistically, there are a few additional points worth knowing. Suramin can interfere with receptor–G protein interactions (affecting GPCR-type P2Y receptors), and because it is polyanionic it may physically compete with nucleotide ligands at receptor binding sites. It has also been shown to affect other receptor families and cellular proteins, so some effects attributed to “anti-purinergic” action may reflect off-target interactions. For this reason suramin is best understood as a broad-spectrum inhibitor of extracellular nucleotide signalling rather than a precise, subtype-selective drug. That makes it a useful research molecule and a candidate for short-term experimental therapy in tightly controlled models, but it limits its attractiveness as a chronic or highly specific therapeutic without further chemical refinement. (DrugBank)

In summary, suramin reduces purinergic signalling principally by blocking P2X and P2Y receptors, which prevents ATP-triggered ion fluxes and G-protein signalling, lowers inflammasome activation and cytokine release, and thereby dampens many nucleotide-driven inflammatory processes. Its non-selective, multi-target nature explains both its experimental utility and the safety limitations that have so far constrained its clinical use beyond specific indications. (PMC)

(Source : ChatGPT)

Purinergic signalling is the cell-to-cell communication system that uses simple purine molecules—mainly extracellular ATP (adenosine triphosphate) and its breakdown product adenosine—to shape immune behaviour. Cells release ATP when they are stressed, injured, or activated; that extracellular ATP is sensed by purinergic receptors on immune and non-immune cells (P2X ion channels and P2Y G-protein coupled receptors). Enzymes on cell surfaces then break ATP down to adenosine, which signals through a different family of receptors (P1 or adenosine receptors). Together these ligands and receptors form a rapid “danger vs. calm” signalling network that helps the immune system decide whether to escalate inflammation or dial it down. (Nature)

Why this matters for autoimmune disease is straightforward in principle: extracellular ATP is a powerful “danger” signal that amplifies inflammation, while adenosine generally suppresses immune responses. When ATP accumulates in tissues it activates receptors such as P2X7 on macrophages, dendritic cells and some lymphocytes; P2X7 activation can open ion channels, trigger assembly of the NLRP3 inflammasome, and drive release of pro-inflammatory cytokines like IL-1β. Those events promote antigen presentation, T-cell activation and inflammatory helper T-cell programs (for example Th17) that are commonly implicated in autoimmune pathology. Conversely, adenosine acting at A₂A and related receptors tends to reduce cytokine production, inhibit T-cell activation and support regulatory pathways that limit tissue damage. An imbalance that favours ATP-driven signalling over adenosine-mediated suppression therefore creates an environment that can sustain or worsen autoimmunity. (ASH Publications)

Several lines of evidence connect purinergic signalling to specific autoimmune conditions. Experimental and human data implicate the P2X7 receptor in diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and neuroinflammatory disorders (including multiple sclerosis), where increased ATP signalling, inflammasome activity, or altered P2X7 expression correlate with tissue inflammation and clinical activity. At the same time, defects in the enzymes that convert ATP to adenosine (for example CD39/CD73), or reduced adenosine receptor signalling, have been observed in settings where immune suppression is lacking, further linking purinergic dysregulation to loss of self-tolerance and chronic inflammation. (PMC)

Mechanistically, multiple immune cell types are affected. Dendritic cells exposed to ATP become more stimulatory and better at activating autoreactive T cells; macrophages respond to P2X7 stimulation by producing inflammasome-dependent cytokines; neutrophils are chemoattracted and activated by nucleotide signals; and T and B lymphocytes change their differentiation and survival according to the local ATP/adenosine balance. Genetic variation or sustained changes in receptor expression can amplify these effects—so purinergic signalling operates both as an acute amplifier of danger signals and as a longer-term modulator of immune set-points that influence whether autoimmunity develops or persists. (MDPI)

Because of its central role, the purinergic system is an attractive therapeutic target, but it is also complicated. Blocking pro-inflammatory nodes such as P2X7 or boosting adenosine signalling (or enhancing the enzymes that make adenosine) can reduce tissue inflammation in animal models and is being tested in humans for several immune conditions. However, these pathways are pleiotropic: the same signals that drive excessive inflammation can be needed for host defence against infection or for normal tissue repair, and adenosine can have context-dependent effects that are not always beneficial. As a result, drug development faces challenges of timing, target specificity, and avoiding immunosuppression that increases infection or cancer risk. Current research therefore aims at selective modulators, cell-type targeted delivery, and identifying the patients and disease stages most likely to benefit. (ScienceDirect)

In short, purinergic signalling contributes to autoimmune disease because it links tissue stress to immune activation (via ATP and receptors like P2X7) while a parallel adenosine pathway normally restrains that response. When the balance tilts toward ATP-driven inflammation—through excess release of nucleotides, receptor overactivity, or failure of adenosine generation—the stage is set for sustained immune activation against self. Understanding and precisely modulating this ATP↔adenosine axis offers a promising but technically demanding route to new treatments for autoimmunity. (Nature)

(Source : ChatGPT)

When the precise language of purinergic signalling breaks down—when the volume of the conversation is turned too high, turned too low, or the messages become garbled—it can contribute to the development or progression of many diseases. Understanding this helps explain why researchers are so focused on developing drugs that can correct this faulty cellular dialogue.

Think back to the city analogy. In a healthy body, the "ATP alert" signal is used for brief, local emergencies—like a construction crew putting up a temporary "Caution" sign to repair a sidewalk. In certain diseases, however, this alert signal gets stuck in the "on" position. This is a major factor in chronic pain disorders, like neuropathic pain. Damaged or over-excited nerves release too much ATP, which constantly screams "Pain!" to neighbouring nerves, even long after the original injury has healed. Similarly, in diseases of chronic inflammation—such as rheumatoid arthritis, inflammatory bowel disease, or atherosclerosis—immune cells release excessive ATP at the site, perpetuating a cycle of inflammation, tissue damage, and more ATP release, much like a false alarm that triggers an endless, damaging emergency response.

Conversely, problems can arise when the calming "adenosine" part of the conversation is too weak or is ignored. In epilepsy, for instance, the brain's neurons become hyperactive and fire in an uncontrolled storm. Normally, adenosine released during brain activity acts as a natural brake to calm this excitement. If this purinergic braking system is insufficient, seizures can propagate. The same principle applies to certain anxiety disorders, where a deficit in calming signals may contribute to a state of persistent neuronal excitability.

Perhaps one of the most profound areas of dysfunction is in neurodegenerative diseases. In conditions like Alzheimer's and Parkinson's disease, the slow, progressive damage to brain cells causes them to leak ATP and other signals. This initially triggers a protective inflammatory response from the brain's immune cells (microglia). But as the disease continues, this purinergic "distress call" is never resolved. The sustained activation of microglia via purinergic receptors pushes them into a harmful, chronic state where they actually begin to damage the very neurons they are supposed to protect, accelerating the disease process.

Finally, cancer cells are notorious hackers of biological systems, and purinergic signalling is no exception. Tumours often create a microenvironment rich in ATP and adenosine. Here, they use the signals to their advantage: the ATP can help fuel dangerous growth and invasion, while the adenosine acts as a powerful immunosuppressant, putting the body's immune cells (like T-cells) to sleep right at the tumour's doorstep. This clever manipulation of the purinergic language allows the cancer to both grow aggressively and hide from the immune system's defences.

Therefore, by developing drugs that can mute the excessive "ATP alarm," boost the calming "adenosine signal," or block the receptors that hear these corrupted messages, scientists aim to create new treatments for pain, inflammation, neurodegeneration, and cancer. They are essentially designing molecular tools to correct the conversation and restore the delicate balance of health.

(Source : DeepSeek)

Here is a plain-language, didactical explanation of purinergic signalling.

Imagine your body is a vast, intricate city. For it to function, millions of messages need to be sent every second between cells—the individual citizens of this city. While we often hear about famous communication systems like hormones or nerve impulses, there is another universal, ancient, and incredibly vital language being spoken all around us: purinergic signalling.

In its simplest form, purinergic signalling is how cells talk to each other using small molecules called purines as their words. The most important of these "words" is a molecule you might know as the body's energy currency: ATP (adenosine triphosphate). For decades, scientists thought ATP's only job was to store energy inside a cell, like a charged battery. The groundbreaking discovery was that cells can also release ATP into the outside environment. When they do this, ATP stops being just an energy packet and becomes a powerful chemical message.

To receive this message, neighbouring cells have antennas on their surface called purinergic receptors. Think of these receptors as specialised locks. When the ATP key fits into its lock (the P2 receptor), it triggers a cascade of events inside the receiving cell, telling it what to do. The instruction might be: "Contract!" if it's a muscle cell, "Fire a signal!" if it's a nerve cell, or "Release inflammation here!" if it's an immune cell.

But the story doesn't end there. This system is beautifully precise. After delivering its message, ATP doesn't just linger and cause chatter. It is quickly broken down by enzymes in the space between cells. ATP becomes ADP, then AMP, and finally adenosine. This final product, adenosine, is not just waste; it's a different word in the same language. Adenosine binds to its own set of locks—the P1 receptors—and delivers a calming, often opposite message. If ATP is the signal for "Activate!" or "Alert!", adenosine is the signal for "Slow down," "Reduce activity," or "Promote healing."

So, why is this mundane-sounding conversation so crucial? Because it is involved in almost every process you can think of. It is fundamental to how you feel pain, how your heartbeat is regulated, how your blood vessels dilate, how your bladder knows when it's full, how your digestive system moves food, and how your immune system mounts a defence. It's the language of immediate, local coordination between cells in almost every tissue of your body.

In summary, purinergic signalling is a universal cellular language where molecules like ATP and adenosine act as words, carrying urgent instructions for action and subsequent commands for restoration. This constant, dynamic dialogue is essential for maintaining the delicate balance of health, and when it goes awry, it contributes to a wide range of diseases, making it a major target for modern drug development.

(Source : DeepSeek)

Suramin is an old, powerful medicine with a very specific set of benefits — and also significant risks. Below I’ll explain, in plain language and with simple science, what suramin can do for health, how it works in broad terms, where evidence is strong versus still preliminary, and why it must be used under careful medical supervision.

Suramin’s clearest and best-established health benefit is as an anti-parasitic drug for African sleeping sickness (human African trypanosomiasis). It kills or stops the growth of the tiny parasites that cause the early (blood and lymph) stage of this disease, and because of that it can prevent the very serious consequences of untreated infection. For that reason suramin appears on major public-health medicine lists and is used in places where the disease occurs; it is supplied as an injection and given under medical supervision. (ICCP Portal)

Beyond parasitic disease, suramin has broad effects on biological signalling that led researchers to test it for other health problems. At the molecular level suramin binds to and blocks a variety of signalling molecules and receptors — for example, it interferes with certain growth factors and with “purinergic” signalling (cell communication that uses molecules like ATP). Those actions can slow parasite metabolism, but they also affect human cells. Because many cancers rely on growth-factor signalling, suramin was investigated as an anti-cancer agent: laboratory and early clinical work showed it can block tumour-promoting signals and, in some small trials, produced anti-tumour effects. However, the cancer results were mixed and the drug’s toxicity limited how useful it became for mainstream cancer treatment. (PubMed)

Another area where suramin has attracted attention is neurological and developmental conditions. In small, carefully controlled research studies, a very low single dose of suramin produced short-term improvements in behavior and communication in a tiny group of children with autism spectrum disorder, and similar effects were seen in mouse models. These results are intriguing because they suggest that blocking certain extracellular signalling pathways might change brain inflammation or metabolism in ways that briefly improve symptoms. But these studies were small, early-stage, and temporary effects faded over weeks; they are not proof that suramin is a safe, effective treatment for autism in general. Larger, longer trials would be required before anyone could recommend it for that purpose. (PMC)

Because suramin acts on many biological pathways it can also cause serious side effects. The most important health caveat is toxicity: suramin can damage nerves (causing peripheral neuropathy), affect kidney function, and cause other systemic problems. Past clinical experiences and animal studies show that neurotoxicity and renal effects are dose-related and can be severe, so dosing and patient monitoring are critical. For these reasons suramin is given in controlled medical settings (intravenous administration with clinical monitoring) and its use outside approved or carefully supervised trials is unsafe. (PMC)

To sum up the balance of benefits and risks in plain language: suramin is a legitimate, sometimes life-saving drug for specific parasitic infections (notably the early stage of African sleeping sickness). Its ability to block multiple signalling pathways has made it a candidate for treating other conditions — cancer, certain inflammatory or metabolic problems, and even experimental autism treatments — but the evidence outside parasitic disease is preliminary, mixed, and limited by safety concerns. Because the same properties that give suramin potential benefits also produce significant side effects, it must only be used where benefits clearly outweigh risks and under experienced medical care or within approved clinical trials. (ICCP Portal)

(Source : ChatGPT)